Patent applications published 7 July 2010

Published: 23-Aug-2010

Selected patent applications from the weekly European Patents Bulletin


  • Synthesis of resveratrol-based natural products
    The Trustees of Columbia University in the City of New York 2203049*

  • Use of R-(+)-N-propargyl-1-aminoindan to treat or prevent hearing loss
    Teva Pharmaceutical Industries 2203050*

  • Octahydropentalene compounds as chemokine receptor antagonists
    Abbott Laboratories 2203051*

  • Modified starch material of biocompatible hemostasis
    Starch Medical 2203053*

  • Stabiliser concentrate for matrix compsns processed at elevated temperatures
    Isp Investments 2203054*

  • 1-methyl nicotinamide and derivatives for treatment of gastric injury
    Cortria Corp 2203055*

  • Controlled release pharmaceutical compsns
    Mulye, Nirmal 2203056*

  • Method and compsns for treatment or prevention of inflammatory conditions
    University of Rochester 2203057*

  • Methods and compounds for modulating cannabinoid activity
    Northeastern University 2203058*

  • Method of treating inherited severe neutropenia
    Merck Sharp &_Dohme; University of Washington 2203059*

  • Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
    Bayer Healthcare 2203060*

  • Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
    Jenrin Discovery 2203061*

  • Methods of inhibiting viral infection
    Functional Genetics 2203065*

  • Compsns and methods using substances containing carbon
    Calera Corp 2203067*

  • Methods of treating gastrointestinal disorders independent of the intake of food
    Takeda Pharmaceuticals North America 2203068*

  • Treatment of pulmonary disorders with aerosolised medicaments such as vancomycin
    Novartis 2203155*

  • Candesartan cilexetil
    Huahai Zheijiang Huahai Pharmaceutical; Alfred E_Tiefenbacher GmbH 2203156*

  • Pharmaceutical formulation for extended release
    AstraZeneca 2203157*

  • Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
    Dr Reddy’s Laboratories 2203158*

  • Dispersion of poloxamer-protein particles, methods of manufacturing and uses thereof
    Institut National de la Sante et de la Recherche Medicale (INSERM); Université d’Angers 2203159*

  • Pharmacological adjunctive treatment associated with glaucoma filtration surgery
    Bausch &_Lomb 2203160*

  • Quinone derivatives, pharmaceutical compsns and uses thereof
    Indiana University Research and Technology 2203161*

  • Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of cancer and angiogenesis
    Indiana University Research and Technology Corp 2203162*

  • Titration package for neramexane and its use in the treatment of inner ear disorder
    Merz Pharma 2203163*

  • Method and apparatus for diagnosis of hemangiosarcoma in mammals
    Veterinary Diagnosis Institute; Colorado State University Research Foundation 2203164*

  • Opthalmic formulation containing paracetamol
    Stellenbosch University 2203165*

  • Bilayer compsns for the sustained release of acetaminophen and tramadol
    Labopharm; Labopharm Europe; Labopharm (Barbados) 2203166*

  • Compound and use thereof in the treatment of amyloidosis
    Pentraxin Therapeutics 2203167*

  • Methods of treating a flaviviridae family viral infection and compsns for treating a flaviviridae family viral infection
    Stanford University 2203168*

  • Glycemic control, diabetes treatment and other treatments with acetyl cholinesterase inhibitors
    Wills, Stephen 2203169*

  • Novel therapeutic uses of adrenergic alpha-1 receptor antagonists
    Sanofi-Aventis 2203170*

  • CB2 receptor ligands for the treatment of pain
    Merck Sharp &_Dohme 2203171*

  • Use of V2 receptor antagonists in combination with vasopressinergic agonists
    Ferring 2203172*

  • Means and methods for counteracting muscle disorders
    Academisch Ziekenhuis Leiden; Prosensa Technologies 2203173*

  • Therapeutic regimens for the treatment of immunoinflammatory disorders
    Combinatorx 2203174*

  • Preparation of wound healing and prevention of bandage adhesion to the wound, containing chitosan-glucan
    CPN_Spol SRO 2203175*

  • Tumour suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
    Celgene Cellular Therapeutics 2203176*

  • Methods and kits for the treatment of diverticular conditions
    Procter &_Gamble 2203177*

  • Estrogenic extracts of Pueraria lobata willd, ohwi of the leguminosae family and uses thereof
    Bionovo 2203178*

  • Vancomycin and teicoplanin anhydrous formulations for topical use
    Pharmatex Italia 2203179*

  • Single IFN-beta fused to a mutated IGG_FC_fragment
    Merck Serono 2203180*

  • An orally administerable solid pharma-ceutical compsn and a process thereof
    Biocon 2203181*

  • Synthetic antigenic peptides and lipo-peptides derived from Mycobacterium avium subsp. paratuberculosis
    Institut National de la Sante et de la Recherche Medicale, Institut National de la Recherche Agronomique; Institut Pasteur 2203182*

  • Medicaments and methods for treating mesothelioma
    Institut Pasteur 2203183*

You may also like